In Big Pharma's growth rankings, Lilly took top spot from Novo Nordisk in Q1

In Big Pharma's growth rankings, Lilly took top spot from Novo Nordisk in Q1

Source: 
Fierce Pharma
snippet: 

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, the first quarter of 2024 nearly matched the final quarter of last year, when 21 of the industry's top 25 companies posted sales increases.